Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1300 participants.
Also called NCT04258488
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,300 participants
- Sponsor
- Joon Bum Kim
- Registry
-
NCT04258488
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT04258488. Randomized; no masking; primary purpose treatment. Start 2022-02-21 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
- Acronym
- RENOVATE
- Condition
- AORTIC VALVE DISEASES
- Condition
- Thromboembolism
- Intervention (Drug)
- Rivaroxaban Oral Tablet
- Intervention (Drug)
- Vitamin K antagonist(warfarin)
- Lead sponsor
- Joon Bum Kim
Record details
- Record id
cardio:ct-nct04258488- Content hash
12fcfd7ba847121e5aea0a76ae95af90d516e75ab743588a2f918f604dd01b85